Log In
BCIQ
Print this Print this
 

Spina bifida risk assessment assay

  Manage Alerts
Collapse Summary General Information
Company VitaPath Genetics Inc.
DescriptionPre-conception, multi-SNP, multi-gene, saliva based assay that predicts the risk of a child being born with spina bifida
Molecular Target
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentPilot
Standard IndicationGenitourinary, Diagnostic
Indication DetailsDiagnose spina bifida
Regulatory Designation
PartnerAlere Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

$8,400.0M

$5,800.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/01/2016

$8,400.0M

$5,800.0M

0

08/15/2011

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today